{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey to establish awareness of the prevalence and treatment landscape of neuropathic pain in Indian patients and role of fixed dose combination of pregabalin and duloxetine in neuropathic pain

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

General Questions
  1. How many patients of peripheral neuropathy do you see in a month? *

  2. What percentage of your peripheral neuropathy patients have neuropathic pain? *

  3. What is the most common age group in which you see peripheral neuropathic pain? *

  4. Which conditions do you most commonly associate with neuropathic pain in your practice? *

  5. What are the key symptoms of neuropathic pain you look for? *

  6. What diagnostic tools or clinical criteria do you use to confirm neuropathic pain? *
  7. What is the typical duration of symptoms before a neuropathic pain diagnosis is made? *

  8. What proportion of your patients self-medicate before visiting you for neuropathic pain? *

  9. What is your first-line treatment for neuropathic pain? *

  10. Do you prefer initiating monotherapy or combination therapy in treatment naïve patients with neuropathic pain? *

  11. Have you seen improved outcomes (e.g., pain reduction, compliance) when switching from pregabalin or duloxetine monotherapy to their FDC? *

  12. In your opinion, what are the main limitations of monotherapy in neuropathic pain management? (Select all that apply) *

  13. How often do you switch therapies due to inadequate pain relief? *

  14. Do you follow any specific clinical guidelines for managing neuropathic pain? If yes, which one? *

  15. What influence your choice of treatment for neuropathic pain? *

  16. Have you prescribed pregabalin + duloxetine FDC in your practice? *

  17. Do patients get better relief with combination therapy? *

  18. What limits your use of combination therapy in neuropathic pain? *
  19. How do you manage neuropathic pain in patients with co-morbid anxiety/depression? *
  20. What are the major unmet needs in neuropathic pain management? *
  21. How often do you see recurrence or worsening of neuropathic pain symptoms after discontinuing therapy? *

  22. Does Pregabalin+ Duloxetine improve treatment adherence? *

  23. How does the Pregabalin+ Duloxetine compare to prescribing both drugs separately? *

  24. What differences in tolerability have you observed with the Pregabalin+ Duloxetine? *
  25. When prescribing the FDC of pregabalin + duloxetine, what is your preferred dosing strategy? *

  26. Does Pregabalin+ Duloxetine improve compliance in Indian patients? *

  27. For which aetiologies is Pregabalin+ Duloxetine most effective? *
  28. In your experience, what percentage of neuropathic pain patients remain refractory to available pharmacotherapy? *

  29. How frequently do you follow up with neuropathic pain patients to assess therapeutic response? *

  30. Have you noticed improved sleep or anxiety outcomes in patients treated with the Pregabalin+ Duloxetine? *

  31. Do you monitor patient-reported outcome measures (e.g., pain scores, quality of life)? *

  32. Would you like to see more head-to-head studies between pregabalin + duloxetine FDC Vs other Gabapentiniod combinations? *

  33. Have you encountered physician resistance to using Combination in your peer group? What were their concerns? *
  34. Which of the following best describes your approach to managing adverse effects of neuropathic pain medications? *

  35. What’s your long-term goal when treating neuropathic pain patients? *

  36. If you had to suggest one improvement to current FDCs (like pregabalin + duloxetine), what would it be and why? *
  37. What role do multidisciplinary approaches (e.g., physiotherapy, psychotherapy, lifestyle changes) play in your management of neuropathic pain? *
  38. In your opinion, what kind of real-world data or local evidence would help establish the value of the pregabalin + duloxetine FDC in Indian practice? *
  39. Are there any emerging treatments or research areas that you find particularly promising for patients with neuropathic pain? *
  40. How do you differentiate patients with Neuropathic pain into 2 treatment groups? *
    41. Sr.No Pregabalin+ Duloxetine Gabapentin + Nortriptyline
    1
    2
    3
    4